SCTX's quality sits well below the engine's investable floor despite notably strong insider buying, with the setup classified as range-bound and speculative given the binary nature of clinical-stage biotech.
Thesis pillars
- Quality Below Floor Biotech→Stable
- Strong Insider Buying Signal→Stable
- Range Bound Technical Setup→Stable
- +1 more pillar — see the Why tab for full reasoning
Scribe Therapeutics Inc. (SCTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $29.50: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company... Read more
Sell if holding. Engine safety override at $29.50: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 5.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-09-14Recent Developments — Scribe Therapeutics Inc.
Latest news
- NEWS HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target — benzinga Sep 3, 2026 positive
- NEWS Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate — benzinga Sep 2, 2026 negative
- NEWS Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday — benzinga Sep 2, 2026 positive
- NEWS HC Wainwright & Co. Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $60 — benzinga Aug 31, 2026 positive
- NEWS Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday — benzinga Aug 28, 2026 neutral
Generated 2026-09-14T07:11:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -97.0%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $29.50: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $27.66. Score 5.0/10, moderate confidence.
Take-profit target: $48.45 (+62.9% upside). Prior stop was $27.66. Stop-loss: $27.66.
Quality below floor (1.5 < 4.0).
Scribe Therapeutics Inc. trades at a P/E of N/A (forward -8.2). TrendMatrix value score: 5.4/10. Verdict: Sell.
10 analysts cover SCTX with a consensus score of 4.3/5. Average price target: $57.
What does Scribe Therapeutics Inc. do?Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic...
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.